ArticleMaterials today. Bio2025
A design-of-experiments strategy for engineering 3D topographical features in osteosarcoma modelling.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evaluating Alternatives to Fetal Bovine Serum in the Development of Advanced Biomaterial-Based Tumor Models: Overcoming Challenges in Biofabrication.Bioengineering (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Osteosarcoma is a highly aggressive bone cancer with poor patient outcomes, partly due to the limited predictive power of current preclinical models. Conventional two-dimensional (2D) cultures fail to recapitulate physiologically relevant cell-matrix interactions, while animal models suffer from interspecies variability. To investigate how extracellular matrix (ECM) topographical features influence osteosarcoma behavior, polylactic acid-based microparticles were engineered with bone-mimetic stiffness and defined surface topographies, guided by a Design-of-Experiments (DoE) approach. This enabled systematic variation of microparticle architecture (8-63 μm diameter; 2-13 μm dimple size) for studying the impact of surface topography on osteosarcoma cell behavior in 3D culture, with doxorubicin treatment as a functional readout to evaluate the effects of 3D topographical cues on chemotherapy sensitivity. Topography was found to modulate cell-microparticle aggregation dynamics. At 96 h post-seeding, MG-63 cells displayed significantly reduced metabolic activity on all 3D microparticle designs, with heterogeneously dimpled-topography cultures displaying significantly lower DNA content than conventional 2D cultures. In U2OS cells, metabolic activity was significantly lower on smooth microparticles compared to dimpled designs, with all 3D cultures showing significantly lower DNA content versus 2D. Response to doxorubicin was more strongly influenced by culture dimensionality than surface topography, underscoring the importance of 3D context. Significant metabolic differences between 3D and 2D cultures were also observed, including the enrichment of amino acid related pathways and downregulation of ferroptosis signatures in 3D microparticle cultures. Topography displayed subtler effects on lipid and nucleotide metabolism. This study highlights how topographically-patterned 3D substrates can shape osteosarcoma cell behavior and drug response for disease modelling applications. Our DoE-guided platform enables systematic investigation for dissecting how ECM-inspired physical cues influence osteosarcoma progression and therapeutic resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.